COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,832 Articles (22,553 medRxiv, 8,279 bioRxiv)

Most recent first Previous |  Page 746: Articles 7451-7460  | Next

Investigating the evolutionary origins of the first three SARS-CoV-2 variants of concern
Ghafari, M., Liu, Q., Dhillon, A., Katzourakis, A., Weissman, D.
10.1101/2022.05.09.491227 — Posted: 2022-05-11
The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample
Barnes, K., Faasse, K., Colagiuri, B.
10.1101/2022.05.09.22274840 — Posted: 2022-05-11
Inhaled CO2 concentration while wearing face masks: a pilot study using capnography.
Acuti Martellucci, C., Flacco, M. E., Martellucci, M., Violante, F. S., Manzoli, L.
10.1101/2022.05.10.22274813 — Posted: 2022-05-11
Machine learning uncovers blood test patterns subphenotypes at hospital admission discerning increased 30-day ICU mortality rates in COVID-19 elderly patients
Zhou, L., Romero-Garcia, N., Badenes, R., Garcia Morales, M. T., Lora, D., Gomez de la Camara, A., Garcia Ruiz, F. T., Garcia-Gomez, J. M., Saez, C.
10.1101/2022.05.10.22274889 — Posted: 2022-05-10
COVID-19 Vaccine Acceptance and Uptake Among Healthcare Workers in Trinidad & Tobago.
Gopaul, C. D., Ventour, D., Thomas, D.
10.1101/2022.05.09.22274854 — Posted: 2022-05-10
Comparative study between first and second wave of COVID-19 deaths in India - a single center study
Tendulkar, P., Pandey, P., Panda, P. K., Bhadoria, A. S., Kulshreshtha, P., Mishra, M., Saxena, G.
10.1101/2022.05.09.22274860 — Posted: 2022-05-10
Activated interstitial macrophages are a predominant target of viral takeover and focus of inflammation in COVID-19 initiation in human lung
Wu, T. T.-H., Travaglini, K. J., Rustagi, A., Xu, D., Zhang, Y., Jang, S. K., Gillich, A., Dehghannasiri, R., Martinez-Colon, G., Beck, A., Wilk, A. J., Morri, M., Trope, W. L., Shrager, J. B., Quake, S. R., Kuo, C. S., Salzman, J., Kim, P. S., Blish, C. A., Krasnow, M. A.
10.1101/2022.05.10.491266 — Posted: 2022-05-10
COVID-19 mRNA third dose induces a unique hybrid immunity-like antibody response
Andreano, E., Paciello, I., Pierleoni, G., Piccini, G., Abbiento, V., Antonelli, G., Pileri, P., Manganaro, N., Pantano, E., Maccari, G., Marchese, S., Donnici, L., Benincasa, L., Giglioli, G., Leonardi, M., De Santi, C., Fabbiani, M., Rancan, I., Tumbarello, M., Montagnani, F., Sala, C., Medini, D., De Francesco, R., Montomoli, E., Rappuoli, R.
10.1101/2022.05.09.491201 — Posted: 2022-05-10
Unrealistic optimism in the eye of the storm: Positive bias towards the consequences of COVID-19 during the second and third waves of the pandemic.
Maksim, A., Spiewak, S., Lipp, N., Duzmanska-Misiarczyk, N., Rebilas, K., Gustaw, G., Strojny, P.
10.1101/2022.05.10.22274918 — Posted: 2022-05-10
BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants
Roessler, A., Netzl, A., Knabl, L., Schaefer, H., Wilks, S. H., Bante, D., Falkensammer, B., Borena, W., von Laer, D., Smith, D., Kimpel, J.
10.1101/2022.05.10.22274906 — Posted: 2022-05-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).